Advertisement

Topics

Xtalks Webinar to Discuss Patient Recruitment Strategies in Prodromal Alzheimer's Disease Clinical Trials

20:00 EDT 18 Oct 2016 | Marketwired

TORONTO, ON--(Marketwired - October 19, 2016) - The webinar taking place on Tuesday, November 1 at 11:00 am. EDT will focus on strategic approaches to identify patients with Prodromal AD and connect them with a study site.

The free 60-minute webinar "Patient Recruitment Strategies in Prodromal Alzheimer's Disease (AD) Clinical Trials" will be led by experts from inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Marie Emms, director, Clinical Trial Recruitment Services, and Robert Smith, PhD, director, Scientific Strategy, will discuss successful patient recruitment strategies for this patient population , including:

Recent advances in Alzheimer's disease (AD) research indicate that the disease has a lengthy prodromal phase that can last as long as 10-12 years, before the onset of a clinically diagnosable disease. As a result, identifying this patient population to evaluate the effects of disease modifying treatments can prove challenging and competitive.

To date, traditional strategies for the recruitment of patients with Prodromal AD have not been successful. Despite being able to reach high numbers of elderly patients with perceived memory problems, finding patients through traditional channels has often funneled large numbers of patients to websites or investigator sites who do not meet study eligibility.

To learn more about this webinar and to register, visit Xtalks' website: http://xtalks.com/Patient-Recruitment-Prodromal-AD.ashx.

About inVentiv Health

inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services, processes and integrated solutions that improve client performance. With more than 15,000 employees and the ability to support clients in 90 countries, our global scale and deep therapeutic expertise enable inVentiv to help clients successfully navigate an increasingly complex environment. For more information, visit inVentivHealth.com.

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, health care centers, etc.) turn to Xtalks for access to quality content. Xtalks helps life science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/sponsorship.ashx.


Forte Research Systems: Why do Recruitment Efforts Fail to Enroll Enough Patients? Lopienski; May 2014
The Cost of Clinical Trial Delays, Ken Getz, Tufts CSDD; January 2015
Cogstate Investor Presentation; June 2014

Image Available: http://www.marketwire.com/library/MwGo/2016/10/18/11G118444/Images/inVentivHealth_Center_RGB_NEW2016-4bbcca72a81d9e6b992aa648cbd67297.jpg

Contact:Dian RazakTel: +1 (416) 977-6555 ext 352Email: NEXT ARTICLE

More From BioPortfolio on "Xtalks Webinar to Discuss Patient Recruitment Strategies in Prodromal Alzheimer's Disease Clinical Trials"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...